Patheon, which provides outsourced contract drug manufacturing and development services, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an IPO that we estimate could...read more
3Q 2014 IPO Market All About BABA and Biotechs The US IPO market raised $37 billion in the third quarter, more proceeds than any quarter since the 4Q99. Most of that capital went to China's e-commerce titan Alibaba (NYSE: BABA), whose record-breaking...read more
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more
Drug making goes Dutch: Pharma outsourcer Patheon files for an IPO that could raise $700 million
Patheon, which provides outsourced contract drug manufacturing and development services, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an IPO that we estimate could...read more
Renaissance Capital's 3Q 2014 US IPO Market Review
3Q 2014 IPO Market All About BABA and Biotechs The US IPO market raised $37 billion in the third quarter, more proceeds than any quarter since the 4Q99. Most of that capital went to China's e-commerce titan Alibaba (NYSE: BABA), whose record-breaking...read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
IPO market brought down by biotech wreck and market sell off
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more